The results indicated that the group of low-level expression of DPT, COL5A2, and CTHRC1 and high-level expression of ECT2 and LRFN4 had a better survival in patients with STAD (Figure 2 and Supplementary Figure 2). This evidence concerns the gene COL5A2 and gastric adenocarcinoma.